104 related articles for article (PubMed ID: 1686240)
1. Pharmacokinetics of iododoxorubicin in the rat, dog, and monkey.
Edwards DM; Marrari P; Efthymiopoulos C; Basileo G; Fraier D; Pianezzola E; Strolin-Benedetti M
Drug Metab Dispos; 1991; 19(5):938-45. PubMed ID: 1686240
[TBL] [Abstract][Full Text] [Related]
2. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio.
Pippa LF; Oliveira ML; Rocha A; de Andrade JM; Lanchote VL
J Pharm Biomed Anal; 2020 Jun; 185():113231. PubMed ID: 32163849
[TBL] [Abstract][Full Text] [Related]
3. Interspecies comparison of the pharmacokinetics of aldose reductase inhibitors.
Brazzell RK; Park YH; Wooldridge CB; McCue B; Barker R; Couch R; York B
Drug Metab Dispos; 1990; 18(4):435-40. PubMed ID: 1976064
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of triclopyr (3,5,6-trichloro-2-pyridinyloxyacetic acid) in the beagle dog and rhesus monkey: perspective on the reduced capacity of dogs to excrete this organic acid relative to the rat, monkey, and human.
Timchalk C; Nolan RJ
Toxicol Appl Pharmacol; 1997 Jun; 144(2):268-78. PubMed ID: 9194410
[TBL] [Abstract][Full Text] [Related]
5. Stereoselectivity of iododoxorubicin reduction in various animal species and humans.
Strolin Benedetti M; Fraier D; Pianezzola E; Castelli MG; Dostert P; Gianni L
Xenobiotica; 1993 Feb; 23(2):115-21. PubMed ID: 8498075
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey.
Adams WJ; McGovren JP; Dalm EA; Brewer JE; Hosley JD
Cancer Res; 1989 Nov; 49(22):6328-36. PubMed ID: 2529962
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of doxorubicin and its active metabolite in patients with normal renal function and in patients on hemodialysis.
Yoshida H; Goto M; Honda A; Nabeshima T; Kumazawa T; Inagaki J; Yamanaka N; Ota K
Cancer Chemother Pharmacol; 1994; 33(6):450-4. PubMed ID: 8137454
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of N-benzyladriamycin-14-valerate in the rat.
Sweatman TW; Seshadri R; Israel M
Cancer Chemother Pharmacol; 1999; 43(5):419-26. PubMed ID: 10100599
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials.
Gianni L; Viganò L; Surbone A; Ballinari D; Casali P; Tarella C; Collins JM; Bonadonna G
J Natl Cancer Inst; 1990 Mar; 82(6):469-77. PubMed ID: 2313718
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma.
Pérez-Blanco JS; Santos-Buelga D; Fernández de Gatta MD; Hernández-Rivas JM; Martín A; García MJ
Br J Clin Pharmacol; 2016 Dec; 82(6):1517-1527. PubMed ID: 27447545
[TBL] [Abstract][Full Text] [Related]
11. Disposition of the antipsychotic agent CI-1007 in rats, monkeys, dogs, and human cytochrome P450 2D6 extensive metabolizers. Species comparison and allometric scaling.
Feng MR; Loo J; Wright J
Drug Metab Dispos; 1998 Oct; 26(10):982-8. PubMed ID: 9763403
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, metabolism and pharmacodynamics of a benzimidazole angiotensin II type 1 receptor antagonist in the beagle dog and cynomologus monkey.
Kakiki M; Ishihara H
Xenobiotica; 1998 Jan; 28(1):77-91. PubMed ID: 9493321
[TBL] [Abstract][Full Text] [Related]
13. Species-differences in disposition and reductive metabolism of methoxymorpholinodoxorubicin (PNU 152243), a new potential anticancer agent.
Breda M; Benedetti MS; Battaglia R; Castelli MG; Poggesi I; Spinelli R; Hackett AM; Dostert P
Pharmacol Res; 2000 Feb; 41(2):239-48. PubMed ID: 10623492
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of mepindolol sulfate in the rat, dog, and rhesus monkey. Studies on species differences.
Krause W; Kühne G
Drug Metab Dispos; 1983; 11(2):91-6. PubMed ID: 6133729
[TBL] [Abstract][Full Text] [Related]
15. Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys.
Radulovic LL; Türck D; von Hodenberg A; Vollmer KO; McNally WP; DeHart PD; Hanson BJ; Bockbrader HN; Chang T
Drug Metab Dispos; 1995 Apr; 23(4):441-8. PubMed ID: 7600909
[TBL] [Abstract][Full Text] [Related]
16. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
17. Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine.
Yoon EJ; Lee WI; Shim HJ; Lee SD; Kim WB; Yang J; Lee MG
Biopharm Drug Dispos; 1996 Jul; 17(5):373-420. PubMed ID: 8830976
[TBL] [Abstract][Full Text] [Related]
18. The effects of lipiodol and cyclosporin A on the hepatobiliary disposition of doxorubicin in pigs.
Dubbelboer IR; Lilienberg E; Hedeland M; Bondesson U; Piquette-Miller M; Sjögren E; Lennernäs H
Mol Pharm; 2014 Apr; 11(4):1301-13. PubMed ID: 24558959
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin area under the curve is an important predictor of neutropenia in dogs with naturally occurring cancers.
Wittenburg LA; Weishaar K; Ramirez D; Gustafson DL
Vet Comp Oncol; 2019 Jun; 17(2):147-154. PubMed ID: 30638304
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of nimodipine. I. Communication: absorption, concentration in plasma and excretion after single administration of [14C]nimodipine in rat, dog and monkey.
Maruhn D; Siefert HM; Weber H; Rämsch K; Suwelack D
Arzneimittelforschung; 1985; 35(12):1781-6. PubMed ID: 4096729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
